Cost-utility estimations of palliative care in patients with pancreatic adenocarcinoma: A retrospective analysis

World Journal of Surgery

Volumn 37, Issue 8, 2013, Pages 1883-1891

  Ljungman, David ^a   Hyltander, Anders ^a   Lundholm, Kent ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; MIDDLE AGED; PALLIATIVE THERAPY; PANCREAS TUMOR; RETROSPECTIVE STUDY; VERY ELDERLY; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; HUMANS; MIDDLE AGED; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84880829880     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-013-2003-z     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54:385-387
3. Sener SF, Fremgen A, Menck HR, et al. (1999) Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189:1-7
4. Sohn TA, Yeo CJ, Cameron JL, et al. (2000) Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-579
5. Schnelldorfer T, Ware AL, Sarr MG, et al. (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247:456-462
6. Ferrone CR, Brennan MF, Gonen M, et al. (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12:701-706
7. Nagakawa T, Sanada H, Inagaki M, et al. (2004) Long-term survivors after resection of carcinoma of the head of the pancreas: significance of histologically curative resection. J Hepatobiliary Pancreat Surg 11:402-408
8. Ljungman D, Lundholm K, Hyltander A (2011) Cost-utility estimation of surgical treatment of pancreatic carcinoma aimed at cure. World J Surg 35:662-670. doi: 10.1007/s00268-010-0883-8
9. Kimura W, Futakawa N, Zhao B (2004) Neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg 11:223-231
10. Lundholm K, Gelin J, Hyltander A, et al. (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54:5602-5606
11. Lundholm K, Daneryd P, Korner U, et al. (2004) Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24:505-512
12. Lindholm E, Daneryd P, Korner U, et al. (2004) Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients. Clin Cancer Res 10:6855-6864
13. Daneryd P, Svanberg E, Korner U, et al. (1998) Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 58:5374-5379
14. Lundholm K, Daneryd P, Bosaeus I, et al. (2004) Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function. Cancer 100:1967-1977
15. Lundholm K, Korner U, Gunnebo L, et al. (2007) Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 13:2699-2706
16. Ware JEJ, Snow KK, Kolinski M, et al. (1993) SF-36 health survey manual and interpretation guide. The Health Institute, New England Medical Center, Boston
17. Sullivan M, Karlsson J, Ware JE Jr (1995) The Swedish SF-36 Health Survey. I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med 41:1349-1358
18. Brazier J, Usherwood T, Harper R, et al. (1998) Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 51:1115-1128
19. Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21:271-292
20. Kopec JA, Willison KD (2003) A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 56:317-325
21. Petrou S, Hockley C (2005) An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 14:1169-1189
22. Barlow WE (2009) Overview of methods to estimate the medical costs of cancer. Med Care 47:S33-S36
23. Barnett PG (2009) An improved set of standards for finding cost for cost-effectiveness analysis. Med Care 47:S82-S88
24. Billingham LJ, Abrams KR (2002) Simultaneous analysis of quality of life and survival data. Stat Methods Med Res 11:25-48
25. Lazaro A (2002) Theoretical arguments for the discounting of health consequences: where do we go from here? Pharmacoeconomics 20:943-961
26. Weinstein MC, Torrance G, McGuire A (2009) QALYs: the basics. Value Health 12(Suppl 1):S5-S9
27. Van den Berg B (2012) SF-6D population norms. Health Econ 21:1508-1512
28. Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, et al. (2005) Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 92:471-477
29. Scheingraber S, Scheingraber T, Brauckhoff M, et al. (2005) Comparison between a general and a disease-specific health-related quality-of-life questionnaire in patients after pancreatic surgery. J Hepatobiliary Pancreat Surg 12:290-297
30. Crippa S, Dominguez I, Rodriguez JR, et al. (2008) Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg 12:783-794
31. Schniewind B, Bestmann B, Henne-Bruns D, et al. (2006) Quality of life after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head. Br J Surg 93:1099-1107
32. Oettle H, Post S, Neuhaus P, et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267-277
33. Heinrich S, Pestalozzi B, Lesurtel M, et al. (2011) Adjuvant gemcitabine versus neoadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 11:346
34. Jeurnink SM, Polinder S, Steyerberg EW, et al. (2010) Cost comparison of gastrojejunostomy versus duodenal stent placement for malignant gastric outlet obstruction. J Gastroenterol 45:537-543
35. Moss AC, Morris E, Mac Mathuna P (2006) Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2:CD004200
36. Hjelmgren J, Berggren F, Andersson F (2001) Health economic guidelines: similarities, differences and some implications. Value Health 4:225-250